Autoantibodies in Hospitalized Patients with COVID-19
Author Information
Author(s): E Tiniakou, L Casciola-Rosen, Mekha A Thomas, Y Manabe, Annukka AR Antar, M Damarla, P M Hassoun, L Gao, Z Wang, S Zeger, A Rosen
Primary Institution: Johns Hopkins University School of Medicine
Hypothesis
Do patients hospitalized with COVID-19 develop autoantibodies against CD209 and CD209L receptors?
Conclusion
IgM autoantibodies against CD209 and CD209L were found in hospitalized COVID-19 patients, but these were not associated with disease severity.
Supporting Evidence
- 19.5% of hospitalized patients had IgM autoantibodies against CD209L.
- 5.9% of patients had antibodies against CD209, all of whom were male.
- Patients with anti-ACE2 IgM had significantly worse outcomes.
Takeaway
Some sick people with COVID-19 have special proteins in their blood that can attack their own body, but these proteins don't seem to make them sicker.
Methodology
The study used enzyme-linked immunosorbent assay (ELISA) to test for autoantibodies in banked samples from hospitalized COVID-19 patients.
Potential Biases
Potential bias due to the limited demographic diversity of the sample.
Limitations
The small size of the study cohort limits the conclusions that can be drawn.
Participant Demographics
Patients aged 18 to 91 years, with a median age of 60; 56% male, 26% White, 41% Black.
Statistical Information
P-Value
0.03 for CAD association, 0.02 for male predominance in anti-CD209L.
Confidence Interval
95% CI: 1.80 (0.69–5.03) for disease severity association.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website